Form 4: Aprea Therapeutics Director Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Bernd R. Seizinger was granted 3,135 restricted stock units and 12,555 stock options by Aprea Therapeutics.
Summary
- Director Bernd R. Seizinger acquired 3,135 restricted stock units (RSUs) on June 16, 2026.
- The director was also granted 12,555 stock options with an exercise price of $0.7293 per share.
- Both the RSUs and the stock options are scheduled to vest in full on June 16, 2027, contingent upon continued service on the board.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Retention of board expertise through long-term vesting schedules.
Negatives
- Potential for future shareholder dilution upon the exercise of options and settlement of RSUs.
Risks
- Vesting is subject to the director's continued service on the board.
- Market price volatility may impact the future value of the granted equity.
Future Outlook
The equity grants are subject to continued service through June 16, 2027, at which point the securities will vest.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure long-term alignment between board members and shareholders, particularly for companies in the development stage.
Comparison to Industry Standards
- The use of time-based vesting for director compensation is consistent with standard corporate governance practices for small-cap biotech firms.
- The grant size is typical for non-executive director compensation packages in the industry.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual vesting and exercise of these equity instruments.
Next Steps
- Vesting of equity awards on June 16, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/16/2026 | Date of grant for restricted stock units and stock options. |
| 06/17/2026 | Date of filing for the Form 4. |
| 06/16/2027 | Vesting date for both RSUs and stock options. |
| 06/16/2036 | Expiration date for the stock options. |
Keywords
Aprea Therapeutics, APRE, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.